Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin - Wikidata - wikimedia - TriplyDB

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

http://www.wikidata.org/entity/Q22250892

about

sameAs

The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome Intention to lose weight, weight changes, and 18-y mortality in overweight individuals without co-morbidities Case-based study: from prediabetes to complications--opportunities for prevention Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan A comprehensive review on metabolic syndrome The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors Erectile dysfunction and central obesity: an Italian perspective Role of insulin in the type 2 diabetes therapy: past, present and future Use of metformin in the setting of mild-to-moderate renal insufficiency 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary].The management of gestational diabetes ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications Metformin and body weight Long-term drug treatment for obesity: a systematic and clinical review Diagnosis and classification of diabetes mellitus Diagnosis and Classification of Diabetes Mellitus The state of US health, 1990-2010: burden of diseases, injuries, and risk factors Applying RE-AIM to the evaluation of FUEL Your Life : a worksite translation of DPP Clinically significant weight gain 1 year after occupational back injury Physical activity and body mass index: the contribution of age and workplace characteristics Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus Interventions for the prevention of type 2 diabetes mellitus in women with previous gestational diabetes Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for development of type 2 diabetes mellitus Acupuncture for adults with type 2 diabetes mellitus Diet and exercise interventions for preventing gestational diabetes mellitus Dietary advice for the prevention of type 2 diabetes mellitus in adults Theory-based behavioural interventions for prediabetic state and people with diabetes mellitus Lifestyle interventions for the treatment of urinary incontinence in adults Group based diabetes self-management education compared to routine treatment, waiting list control or no intervention for people with type 2 diabetes mellitus Metformin monotherapy for type 2 diabetes mellitus Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries Physical exercise for type 1 diabetes mellitus Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

P2860

Q21093273-51F86C69-8BB9-46C0-8656-A3FCF4E8253F Q21144722-9DE38060-D801-413C-A50C-E4AAEA48B44E Q21144738-C71FBBC0-64C7-45D1-89E8-02B9ACC1602A Q21245262-2F1F7DFF-435F-425A-90F2-FFA8B98552BA Q21284500-92BADAC5-E9F6-4BFA-A949-78599BFCD5EB Q21296864-FA97C976-6FF0-4647-904C-31DC4F45E078 Q21560863-AE120B89-1D49-4F44-B712-E1F7BEC044F2 Q21563356-BCBBBCF5-975D-4539-80CE-AF000088828F Q21563399-C779C1BB-37DD-4185-9941-F3C983127B87 Q22241096-CC83EB22-EEA8-49A3-845D-DB296F6DF421 Q22241148-41D84C59-8673-4D19-9C36-0A4F0A082861 Q22241290-39384B4D-23C6-4301-895A-A406E2D08049 Q22241393-940892A6-7A16-43CA-9D5E-9E2BAEEE9007 Q22241441-A971E49D-3743-4B8B-AEF2-C1FD4E7BD257 Q22241786-6E0A0913-082C-40BB-9DD1-B00A2A65D7A1 Q22242884-2C92F1F4-20A3-4E04-922A-BEFDD80E0BC5 Q22250988-36702A29-127A-4B2C-A693-217DE51AC0DC Q22253010-9986FA77-2E5F-4AB0-B6D9-43921D2FC92E Q22255452-9C525072-D8BB-4C7F-9D94-EC9B8087CD8D Q22255454-8DAB7B67-77CD-4542-8A6A-2F17BBC6139E Q23909354-13259979-5AA4-435C-8658-EA76E0775F6A Q23909875-6F2FC5B9-6760-4A4F-8C39-9A24DBCC0763 Q23910365-0F3B3292-19A4-4BF7-A836-C89240E2839F Q24169773-627061AA-31DF-4C18-9F81-B8623DBD991A Q24185805-EFFFC12F-EF64-47DC-8468-B80922BD1B62 Q24185836-ECFA5252-6882-4B63-A766-CC1A4C6C650F Q24185874-71ADEBE7-6041-4D65-9654-381920E8AE7A Q24185970-6ADBC2D4-DF19-4931-8085-9D47A416C60D Q24186087-67642A43-B642-440F-97AF-93E742CDEF15 Q24186271-A0DA256C-D549-4877-A085-730BD6A37D14 Q24186535-8F08D9BA-8212-4C18-94B5-2A57A93044D8 Q24186597-65948808-C468-4CBF-B2C9-B2CE904F5728 Q24186851-7E3DD03C-D778-4742-A8ED-2250829F6F05 Q24187247-9472C28F-D75B-4036-92B9-CF22C8565DC1 Q24187367-D3023B4D-014A-445D-BC92-05E517E11DB7 Q24187392-78A92B7D-1B0F-4A92-8FFC-7CA592B78B52 Q24188028-D6BF970D-80CA-48F0-9784-D579169A96F5 Q24194237-7DBB5125-ED25-4587-B9F6-2CC0C74C355E Q24195176-97678F92-EE41-4C0F-8F2B-0BFB963EBBF7 Q24197673-5FB56E1C-7212-4023-8C61-FB2A006636F5

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

http://www.wikidata.org/entity/Q22250892

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@ast

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@en

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@en-gb

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@nl

type

label

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@ast

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@en

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@en-gb

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@nl

altLabel

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

@en

prefLabel

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@ast

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@en

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@en-gb

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@nl

P1433

Q22250892-8D71BA17-64F2-4408-A3D4-18B96D6764E5

P1476

Q22250892-217EB9C0-D9C6-4020-A186-274153CAC6BE

Q22250892-CC5269A1-2830-43DC-8464-D3B238C84A38

P2093

Q22250892-1748BD82-71B3-4E9F-BD4E-906F8DEA39DB

Q22250892-6A42FA04-2A47-454B-9A01-F9B4B228CB10

Q22250892-81643808-0C46-4BC2-9F63-9FF09ED48A0D

Q22250892-F5FAC0A8-1FEB-44AB-81C2-8772B1325239

P2860

Q22250892-194B16B0-2EA0-4C53-A675-8FF89EC59CE2

Q22250892-29749FC9-FD95-4226-8068-D33D4DC68DA8

Q22250892-2D0C1C9A-E6C7-494B-8546-156BDF23A61C

Q22250892-3F3311C3-236F-4285-B01D-FCE19074B1C0

Q22250892-4EC11482-4557-4DE4-9F43-9D5B7C632087

Q22250892-63C7AD16-19CC-4695-9FAC-6C6BF6926646

Q22250892-7998B931-519E-47CF-A5CE-E1A668F47831

Q22250892-82E670AE-BFFB-4C0E-B391-16DA6013BDEC

Q22250892-867E5102-7BB4-4C69-B31C-5832C98692D0

Q22250892-89A6AA0A-D0B8-4494-98A7-C65CEF292DFA

P304

Q22250892-EFA7A401-0461-48BF-AA0C-351946EFE708

P31

Q22250892-F5C33C2F-4869-4E8F-A14C-0E60A960211D

P3181

Q22250892-DAD3C36B-446A-4E83-BE59-279936137F6F

P356

Q22250892-CCEBFB6E-F6AE-4330-BB77-FE5800363217

P407

Q22250892-44C118FD-6506-4B89-B65C-6D8E5422C0A9

P433

Q22250892-5F6A7D25-8607-4377-9E37-C587DD46BEC5

P478

Q22250892-3902EA29-2D84-435C-A541-AA2A66FB0C16

P50

Q22250892-34119A37-F236-4D2E-AFDA-E186620974CE

Q22250892-4DD9CB6E-6D99-4421-A841-535A8172363E

Q22250892-F5C33937-7FF7-4FDB-A759-AA3EC69EA735

P577

Q22250892-0AEF38BE-7ECF-451A-9313-9CB80324AD60

P698

Q22250892-6DC8C7B8-AE80-4216-AC5F-9201E4D3F43A

P921

Q22250892-66295771-46F2-46C3-ADA5-99E874D6EC95

Q22250892-AC1BD6E8-4932-494F-9538-030CC9E1D7C3

P932

Q22250892-2A97B471-6124-4735-B805-41CBE0EC0FD2

P3181

P356

P1433

The New England Journal of Medicine

P1476

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

@en

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin

@en

P2093

David M Nathan

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Walker

http://www.w3.org/2001/XMLSchema#string

Richard F Hamman

http://www.w3.org/2001/XMLSchema#string

Sarah E Fowler

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

Pharmacologic therapy for type 2 diabetes mellitus.

Early detection of undiagnosed diabetes mellitus: a US perspective.

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies

Validity and reproducibility of a food frequency interview in a Multi-Cultural Epidemiology Study.

P304

393-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

29339

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA012512

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

346

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Barrett-Connor

William C. Knowler

P577

2002-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11832527

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

1370926

http://www.w3.org/2001/XMLSchema#string